Objective:To perform drug sensitivity experiments on patient-derived oral squamous cell carcinoma(OSCC)organoid models and to design individualized drug therapies for the corresponding patients.Mehthods:In the present study,patient-derived organoid(PDO)models were established by obtaining fresh specimens through biopsy or radical operation.These models were used to determine the sensitivity of six drugs(cisplatin,paclitaxel,5-FU,Cetuximab,Alpelisib,and Nutlin-3)to OSCC.Four of the biopsy patients were given individualized medica-tion according to the experimental results and the short-term therapeutic effect was observed after two courses of treatment.Results:Ten OSCC organoids were successfully established(success rate=10/12,83.3％),which could be stably passaged and amplified for more than four generations.The histopathology characteristics of OSCC were highly consistent with those of their parental tumor tissues.The PDO models derived from different patients showed individual differences in the results of drug sensitivity tests.The tumor control results of 4 biopsy patients all met the partial remission criteria,which were consistent with the experimental results.Conclusion:The his-topathological characteristics of the established OSCC PDO models were highly similar to those of their parental tumors.The results of the in vitro drug sensitivity tests based on these models were consistent with the clinical treatment response of the corresponding patients,laying a foundation for the establishment of a new individualized and precise drug treatment system for OSCC.
维普
万方数据